PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231

Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies

Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99

Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics

Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191009 · Cited by 96

Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities

Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.7421 · Cited by 96

Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer

Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96

Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states

Wei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97

Cardiotoxicity of Anticancer Therapeutics

Dong, J., & Chen, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00009 · Cited by 95

Engineering chimeric antigen receptor-T cells for cancer treatment

Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95

Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them

Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87

Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors

Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma

Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92

Ganetespib: research and clinical development

Modi, S., & Jhaveri, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s65804 · Cited by 92

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

(2021) · doi:10.1038/s43018-021-00190-z · Cited by 92

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy

Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91

An integrative deep learning framework for classifying molecular subtypes of breast cancer

Mohaiminul Islam, M., Huang, S., Ajwad, R., Chi, C., Wang, Y., & Hu, P. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.005 · Cited by 90

Product review: Avelumab, an anti-PD-L1 antibody

Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions

Ghoreyshi, N., Heidari, R., Farhadi, A., Chamanara, M., Farahani, N., Vahidi, M., & Behroozi, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-01816-9 · Cited by 91

Local iron homeostasis in the breast ductal carcinoma microenvironment

Marques, O., Porto, G., Rêma, A., Faria, F., Cruz Paula, A., Gomez-Lazaro, M., Silva, P., Martins da Silva, B., & Lopes, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2228-y · Cited by 90

Systemic immune-inflammation index in germ-cell tumours

Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations

Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0402 · Cited by 89

Immunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival

Coronel, M. M., Martin, K. E., Hunckler, M. D., Barber, G., O’Neill, E. B., Medina, J. D., Opri, E., McClain, C. A., Batra, L., Weaver, J. D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5573 · Cited by 89

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors

Wang, X., Barrera, C., Bera, K., Viswanathan, V. S., Azarianpour-Esfahani, S., Koyuncu, C., Velu, P., Feldman, M. D., Yang, M., Fu, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3966 · Cited by 89

Melanoma and microbiota: Current understanding and future directions

Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89

High intratumoral CD8 + T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy

Yang, Y., Attwood, K., Bshara, W., Mohler, J. L., Guru, K., Xu, B., Kalinski, P., & Chatta, G. (2021) · The Prostate · doi:10.1002/pros.24068 · Cited by 88

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

Arakawa, A., Vollmer, S., Tietze, J., Galinski, A., Heppt, M. V., Bürdek, M., Berking, C., & Prinz, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01336 · Cited by 74

Immune-mediated drug-induced liver injury: immunogenetics and experimental models

Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87

Phase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer

Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81

Kras and tumor immunity: friend or foe?

Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

Glitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0066 · Cited by 87

Immunological Effects of the TGFβ-Blocking Antibody GC1008 in Malignant Pleural Mesothelioma Patients

Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86

Haematological malignancies: at the forefront of immunotherapeutic innovation

Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85

Extracting Intercellular Signaling Network of Cancer Tissues using Ligand-Receptor Expression Patterns from Whole-tumor and Single-cell Transcriptomes

Zhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85

Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells

Peters, A. A., Jamaludin, S. Y. N., Yapa, K. T. D. S., Chalmers, S., Wiegmans, A. P., Lim, H. F., Milevskiy, M. J. G., Azimi, I., Davis, F. M., Northwood, K. S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.234 · Cited by 85

Beyond Endometriosis Genome-Wide Association Study: From Genomics to Phenomics to the Patient

Rahmioglu, N., Morris, A., Nyholt, D., Montgomery, G., Becker, C., Missmer, S., & Zondervan, K. (2016) · Seminars in Reproductive Medicine · doi:10.1055/s-0036-1585408 · Cited by 84

PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF

Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83

The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose

Kumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0234-3 · Cited by 81

CRISPR-mediated genome editing and human diseases

Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.07.003 · Cited by 83

Multi-parametric MRI-based radiomics models for predicting molecular subtype and androgen receptor expression in breast cancer

Huang, Y., Wei, L., Hu, Y., Shao, N., Lin, Y., He, S., Shi, H., Zhang, X., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706733 · Cited by 82

Entinostat induces antitumor immune responses through immune editing of tumor neoantigens

Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling

Siska, P. J., Johnpulle, R. A. N., Zhou, A., Bordeaux, J., Kim, J. Y., Dabbas, B., Dakappagari, N., Rathmell, J. C., Rathmell, W. K., Morgans, A. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1305535 · Cited by 82

Inhibition of UBA6 by inosine augments tumour immunogenicity and responses

(2022) · doi:10.1038/s41467-022-33116-z · Cited by 82

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

Horisberger, A., La Rosa, S., Zurcher, J.-P., Zimmermann, S., Spertini, F., Coukos, G., & Obeid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0481-0 · Cited by 81

STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers

Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80

Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAβ knockout NOD mice

Elliott, J. F., Liu, J., Yuan, Z.-N., Bautista-Lopez, N., Wallbank, S. L., Suzuki, K., Rayner, D., Nation, P., Robertson, M. A., Liu, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235552100 · Cited by 80

Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma

Koh, J., Kim, S., Kim, M.-Y., Go, H., Jeon, Y. K., & Chung, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14632 · Cited by 77

Identification of topological features in renal tumor microenvironment associated with patient survival

Cheng, J., Mo, X., Wang, X., Parwani, A., Feng, Q., & Huang, K. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx723 · Cited by 79

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Olsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0098-5 · Cited by 78

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 77

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report

Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., & Narita, I. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0848-y · Cited by 77

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76

Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells

Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0009-7 · Cited by 76

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75

Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells

Yoh, K. E., Regunath, K., Guzman, A., Lee, S.-M., Pfister, N. T., Akanni, O., Kaufman, L. J., Prives, C., & Prywes, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613417113 · Cited by 75

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75

Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors

Lu, J.-C., Zeng, H.-Y., Sun, Q.-M., Meng, Q.-N., Huang, X.-Y., Zhang, P.-F., Yang, X., Peng, R., Gao, C., Wei, C.-Y., et al. (2019) · Theranostics · doi:10.7150/thno.36276 · Cited by 72

The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth

Büchau, A. S., Morizane, S., Trowbridge, J., Schauber, J., Kotol, P., Bui, J. D., & Gallo, R. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902110 · Cited by 73

Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment

Jin, Y., An, X., Mao, B., Sun, R., Kumari, R., Chen, X., Shan, Y., Zang, M., Xu, L., Muntel, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07153-z · Cited by 73

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities

Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73

Characterization of potential driver mutations involved in human breast cancer by computational approaches

Rajendran, B. K., & Deng, C.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17225 · Cited by 73

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2374954 · Cited by 74

Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter

Redmer, T. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0854-5 · Cited by 67

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy

Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28

Zhang, C., Fan, Y., Che, X., Zhang, M., Li, Z., Li, C., Wang, S., Wen, T., Hou, K., Shao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00760 · Cited by 69

Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models

Reason, T., Benbow, E., Langham, J., Gimblett, A., Klijn, S. L., & Malcolm, B. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00476-9 · Cited by 71

Age-associated inflammation connects ras-induced senescence to stem cell dysfunction and epidermal malignancy

Golomb, L., Sagiv, A., Pateras, I. S., Maly, A., Krizhanovsky, V, Gorgoulis, V. G., Oren, M., & Ben-Yehuda, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.21 · Cited by 71

Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies

Kudo, M. (2019) · Liver Cancer · doi:10.1159/000503254 · Cited by 70

The effects of age and systemic metabolism on anti-tumor T cell responses

Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0125-3 · Cited by 69

Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy

Fenizia, F., Pasquale, R., Roma, C., Bergantino, F., Iannaccone, A., & Normanno, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.23 · Cited by 69

p16Ink4a and p21Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis

Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Tremblay-LeMay, R., Rastgoo, N., & Chang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0589-1 · Cited by 69

The Pathogenesis of Tuberculosis-The Koch Phenomenon Reinstated.

Hunter, R. L. (2020) · Pathogens · doi:10.3390/pathogens9100813 · Cited by 67

Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Lim, E. L., Cugliandolo, F. M., Rosner, D. R., Gyori, D., Roychoudhuri, R., & Okkenhaug, K. (2018) · JCI Insight · doi:10.1172/jci.insight.120626 · Cited by 66

Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts

Zhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66

Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety

Young, P. A., Morrison, S. L., & Timmerman, J. M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.002 · Cited by 66

Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab

Baxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180870 · Cited by 65

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

Qin, L., Li, X., Stroiney, A., Qu, J., Helgager, J., Reardon, D. A., & Young, G. S. (2017) · Neuroradiology · doi:10.1007/s00234-016-1769-8 · Cited by 64

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63

Considerations for successful cancer immunotherapy in aged hosts

Hurez, V, Padrón, Á. S., Svatek, R. S., & Curiel, T. J. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12875 · Cited by 65

High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma

Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020) · Science Advances · doi:10.1126/sciadv.aba5542 · Cited by 63

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64

Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes

Lee, Y.-H., Bae, H. C., Noh, K. H., Song, K.-H., Ye, S.-K., Mao, C.-P., Lee, K.-M., Wu, T.-C., & Kim, T. W. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1979 · Cited by 64

BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion

Sethuraman, A., Brown, M., Krutilina, R., Wu, Z.-H., Seagroves, T. N., Pfeffer, L. M., & Fan, M. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1046-3 · Cited by 63

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911571 · Cited by 62

Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative

Rydén, L., Loman, N., Larsson, C., Hegardt, C., Vallon-Christersson, J., Malmberg, M., Lindman, H., Ehinger, A., Saal, L. H., & Borg, Å. (2018) · British Journal of Surgery · doi:10.1002/bjs.10741 · Cited by 62

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Liu, S., Chen, B., Burugu, S., Leung, S., Gao, D., Virk, S., Kos, Z., Parulekar, W. R., Shepherd, L., Gelmon, K. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2085 · Cited by 57

Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58

KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer

Zhang, C., Zhang, X., Zhao, W., Zeng, C., Li, W., Li, B., Luo, X., Li, J., Jiang, J., Deng, B., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2308-9 · Cited by 61